Tumor News and Research

RSS

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme.

30 Jul 2013

Trovagene adopts RainDance's RainDrop digital PCR system for eventual use in CLIA laboratory

Trovagene, Inc. (NASDAQ: TROV) and RainDance Technologies announced today that Trovagene has adopted RainDance's RainDropTM Digital PCR System for research and development, and for eventual use in the Trovagene CLIA laboratory.

29 Jul 2013

Weekend reading: The mystery of some innovations that are slow to be accepted; myths about the obesity crisis

Why do some innovations spread so swiftly and others so slowly? Consider the very different trajectories of surgical anesthesia and antiseptics. ... On October 16, 1846, at Massachusetts General Hospital, Morton administered his gas through an inhaler in the mouth of a young man undergoing the excision of a tumor in his jaw. ... By February, anesthesia had been used in almost all the capitals of Europe, and by June in most regions of the world.

26 Jul 2013

Rapamycin extends mice lifespan but has limited effects on aging

The body's repair mechanisms begin to fail with increasing age. As a result, signs of wear and tear appear and the risk for many diseases, including Alzheimer's disease, diabetes, cardiovascular disorders and cancer, increases.

26 Jul 2013

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Emergency physicians correctly identify nearly 100% of patients with Bell's palsy

Emergency physicians correctly identified nearly 100 percent of patients with Bell's palsy, the symptoms of which are nearly identical to potentially life-threatening diseases such as stroke and brain tumors.

26 Jul 2013

Finding could aid in delivering personalized cancer medicine based on individual's genetics

Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics.

26 Jul 2013

EPHB2 overexpressed in malignant pleural mesothelioma cell lines, find researchers

Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis. Increased understanding of the molecular basis for the diverse signaling pathways involved in cancer progression should promote the discovery of novel biomarkers for early diagnosis and potentially lead to more effective therapeutic tools for the disease.

26 Jul 2013

Gene expression profile test accurately predicts likelihood of metastasis in thymoma patients

Patients diagnosed with thymoma, a rare cancer of the thymus gland, may be able to avoid certain cancer treatments associated with severe adverse events if the results of a new test reveal they are at low risk of metastasis, according to a study published today in the journal PLOS ONE.

25 Jul 2013

NIST scientists develop new standard reference material to enable hospitals calibrate CAT scanners

Scientists at the National Institute of Standards and Technology have developed a new standard reference material, the first such measurement tool to enable hospitals to link important tissue density measurements made by CAT scans to international standards.

25 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

New data questions surgical options for treating kidney cancer

Surgery is often the first step in treating kidney cancer, and new data from the University of Rochester Medical Center, which contradicts earlier research, questions whether removal of only the tumor (partial nephrectomy) is better than removing the entire kidney (radical nephrectomy).

25 Jul 2013

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Judith Villablanca, MD, of The Saban Research Institute of Children's Hospital Los Angeles, Susan Kreissman, MD, of Duke University Medical Center, and colleagues reported the results of a randomized, phase 3 clinical trial conducted by the Children's Oncology Group examining the effect of selectively removing (purging) tumor cells from blood stem cells before they are transplanted back into patients with high-risk neuroblastoma following high-dose chemotherapy.

25 Jul 2013

Study reveals that black women with breast cancer continue to have lower survival rate

In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.

25 Jul 2013

New clinic focuses on men with fast-growing prostate cancer

While every year about 30,000 men die of prostate cancer in the United States, the most common cause of death in men with prostate cancer is heart disease. That's because not all prostate cancers are the same. Some are slow-growing while others are very aggressive.

25 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

OracleBio, providers of high precision digital image analysis services for detailed quantification of histological marker staining within cells and tissues, is pleased to announce it will be a principal sponsor of the forthcoming Tumor Models conference to be held in Boston, MA on the 23-25th July.

24 Jul 2013

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Back in the early 1960s, just before chemotherapy really started to be used, only about 30% of children survived cancer. That was mainly because they had cancers that were amenable to surgery.

24 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Tumor News and Research

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

Trovagene adopts RainDance's RainDrop digital PCR system for eventual use in CLIA laboratory

Weekend reading: The mystery of some innovations that are slow to be accepted; myths about the obesity crisis

Rapamycin extends mice lifespan but has limited effects on aging

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Emergency physicians correctly identify nearly 100% of patients with Bell's palsy

Finding could aid in delivering personalized cancer medicine based on individual's genetics

EPHB2 overexpressed in malignant pleural mesothelioma cell lines, find researchers

Gene expression profile test accurately predicts likelihood of metastasis in thymoma patients

NIST scientists develop new standard reference material to enable hospitals calibrate CAT scanners

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

New data questions surgical options for treating kidney cancer

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Study reveals that black women with breast cancer continue to have lower survival rate

New clinic focuses on men with fast-growing prostate cancer

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News